Partners, Llc Melkonian Cap... Net Worth

The estimated Net Worth of Partners, Llc Melkonian Cap... is at least 8 百万$ dollars as of 5 September 2019. Partners Cap owns over 65,000 units of Progenics Pharmaceuticals stock worth over 7,995,000$ and over the last 5 years Partners sold PGNX stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Partners Cap PGNX stock SEC Form 4 insiders trading

Partners has made over 1 trades of the Progenics Pharmaceuticals stock since 2019, according to the Form 4 filled with the SEC. Most recently Partners bought 65,000 units of PGNX stock worth 307,450$ on 5 September 2019.

The largest trade Partners's ever made was buying 65,000 units of Progenics Pharmaceuticals stock on 5 September 2019 worth over 307,450$. On average, Partners trades about 65,000 units every 0 days since 2019. As of 5 September 2019 Partners still owns at least 1,950,000 units of Progenics Pharmaceuticals stock.

You can see the complete history of Partners Cap stock trades at the bottom of the page.

Insiders trading at Progenics Pharmaceuticals

Over the last 22 years, insiders at Progenics Pharmaceuticals have traded over 11,559,939$ worth of Progenics Pharmaceuticals stock and bought 2,672,016 units worth 11,900,148$ . The most active insiders traders include Healthcare Master Fund Ltd ...、Michael D Kishbauch、Bradley L Campbell. On average, Progenics Pharmaceuticals executives and independent directors trade stock every 16 days with the average trade being worth of 60,241$. The most recent stock trade was executed by Capital, L.P.Altiva Managem... on 9 September 2019, trading 72,023 units of PGNX stock currently worth 359,395$.

What does Progenics Pharmaceuticals do?

Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J. Maddon in 1986 and is headquartered in New York, NY.

Complete history of Partners Cap stock trades at Progenics Pharmaceuticals

Progenics Pharmaceuticals executives and stock owners

Progenics Pharmaceuticals executives and other stock owners filed with the SEC include:

• Partners, Llc Melkonian Cap...,
  
• Nicole Williams,
  Director
• Healthcare Master Fund Ltd ...,
  
• Healthcare Master Fund Ltd ...,
  
• Sheldon Hirt,
  Executive VP & General Counsel
• Michael D Kishbauch,
  Director
• David A Scheinberg,
  Director
• Karen Jean Ferrante,
  Director
• Peter J Crowley,
  Director
• Bradley L Campbell,
  Director
• Jeffery Summer,
  SVP, Digital Technology
• Patrick Fabbio,
  CFO
• Mark Robert Baker,
  CEO
• Charles A Baker,
  Director
• Kurt W Briner,
  Director
• Stephen P Goff,
  Director
• Mark F Dalton,
  Director
• Thomas A Boyd,
  SR. VP, Product Development
• Paul F Jacobson,
  Director
• Robert A Mckinney,
  VP of Finance and Admin
• Alton B Kremer,
  VP, Clinical Research
• Robert J Israel,
  Senior VP Medical Affairs
• Philip K Yachmetz,
  VP, Gen Counsel and Secretary
• Ronald J Prentki,
  President
• William C Olson,
  Senior VP, Research and Develo
• Paul J Maddon,
  Director
• Angelo William Jr Lovallo,
  Vice President Finance
• Hagop Youssoufian,
  Executive Vice President R&D
• Capital, L.P.Altiva Managem...,
  
• Heinz Christoph Maeusli,
  Director
• Gerard Ber,
  Director
• Ann L. Mac Dougall,
  Director
• Eric J Ende,
  Director
• Vivien Wong,
  EVP, Development
• David W. Mims,
  Interim CEO and Interim CFO
• Bryce Tenbarge,
  SVP, Commercial
• Benedict Osorio,
  COO
• Asha Das,
  Chief Medical Officer